![Rosemary Harrison](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Rosemary Harrison
Corporate Officer/Principal at TCR2 THERAPEUTICS INC.
Rosemary Harrison active positions
Companies | Position | Start | End |
---|---|---|---|
TCR2 THERAPEUTICS INC. | Corporate Officer/Principal | 2021-12-31 | - |
Career history of Rosemary Harrison
Former positions of Rosemary Harrison
Companies | Position | Start | End |
---|---|---|---|
TRILLIUM THERAPEUTICS | Investor Relations Contact | - | 2021-10-31 |
Corporate Officer/Principal | 2020-11-04 | 2021-10-31 | |
Imbria Pharmaceuticals, Inc.
![]() Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Corporate Officer/Principal | 2019-05-31 | 2020-02-29 |
Novartis Institutes for Biomedical Research, Inc.
![]() Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 2015-02-28 | 2018-04-30 |
Training of Rosemary Harrison
The University of Queensland | Doctorate Degree |
Statistics
International
United States | 4 |
Canada | 2 |
Australia | 2 |
Operational
Corporate Officer/Principal | 4 |
Investor Relations Contact | 1 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 4 |
Consumer Services | 2 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 4 |
---|---|
Trillium Therapeutics ULC
![]() Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
TCR2 Therapeutics, Inc.
![]() TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
![]() Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
Imbria Pharmaceuticals, Inc.
![]() Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Rosemary Harrison
- Experience